Ilika plc Half year report reflects increased corporate interest

Ilika plc

Ilika Plc (LON:IKA), a pioneer in solid-state battery technology and materials innovation, announced today its unaudited half yearly report for the six months ended 31 October 2017.

Operational Highlights

· Exchanged detailed Stereax® performance data with over 60 potential OEM partners

· Shipped sample batteries to 10 potential OEM partners for detailed technical evaluation

· Three of these have progressed to development and deployment partnerships:

o Advanced a development programme to integrate a Stereax® battery in a miniature medical implant product (value to Ilika of £700,000 over 18 months from March 2017)

o Commenced a development programme to integrate a Stereax® battery with a photovoltaic energy harvesting solution from Lightricity (ex-Sharp) (value to Ilika of £320,000 over two years from July 2017)

o Secured a deployment programme with Titan Wind Energy, China’s largest wind turbine manufacturer, to use Stereax® M250 batteries to power strain sensors for turbine blade condition monitoring (value to Ilika of £400,000 over two years from March 2018)

· Continued to implement the Stereax® roadmap to achieve increased capacity per footprint and miniaturisation requirements

· Executed the following materials development programmes:

o plasmonic lenses and Heat Assisted Magnetic Recording (HAMR) materials with Seagate

o battery materials with Johnson Matthey

o game changing energy materials with Toyota and

o aerospace alloys in collaboration with partners including Rolls Royce, GKN and BAE Systems.

· Expanded proprietary IP with patents granted in USA for core-shell catalysts for fuel cells

· ISO 9001Certification achieved in December 2017

Financial Summary

· Total revenue for the period £1.0m (H1 2016: £0.3m)

· Loss per share 2p (H1 2016: 3p per share)

· Cash balance at period end £3.9m (H1 2016: £7.1m)

Commenting on the results Graeme Purdy, CEO of Ilika Plc, said: “In the first half of the year Ilika has delivered a series of Stereax® development and deployment partnerships which are driving revenue growth and enhancing insight into the addressable sectors for its technology. The progress being made towards the commercialisation of Stereax technology is illustrated by the increased number of Stereax® samples sent to a diverse range of potential OEM partners for evaluation. Ilika is well-positioned to generate value from its globally-recognised reputation for expertise in solid-state materials and battery technology and is seeing increased corporate interest consistent with greater activity in the global battery sector.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika completes PRIMED programme with improved Goliath battery performance

Ilika has completed its £3 million PRIMED programme, reporting improved energy density, charging, power, cycle life and thermal stability for its 10Ah Goliath solid-state battery cells, alongside new commercial opportunities in defence, e-bikes and other applications.

Ilika to present UK-developed quasi-solid-state cell technology at Faraday Event

Ilika will present its UK-developed quasi-solid-state cell technology at The Faraday Institution’s Next Frontiers in Energy Storage event on Tuesday 8 September.

Ilika targets MedTech adoption with Stereax solid-state batteries

Ilika is targeting medical device and IoT applications with its Stereax miniature solid-state batteries, supported by a manufacturing and commercialisation agreement with Cirtec Medical.

Ilika confirms AGM date and Annual Report posting

Ilika has given notice of its 2026 Annual General Meeting and said its annual report and AGM notice will be available shortly.

Ilika targets medical device opportunities with Stereax at MedTech Ireland

Ilika’s Stereax technology will be presented at MedTech Ireland 2026 as the company targets further opportunities in active implanted medical devices.

Search